{"id":"https://openalex.org/W2092986324","doi":"https://doi.org/10.1097/ppo.0b013e3180465940","title":"Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer","display_name":"Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer","publication_year":2007,"publication_date":"2007-03-01","ids":{"openalex":"https://openalex.org/W2092986324","doi":"https://doi.org/10.1097/ppo.0b013e3180465940","mag":"2092986324","pmid":"https://pubmed.ncbi.nlm.nih.gov/17476141"},"language":"en","primary_location":{"id":"doi:10.1097/ppo.0b013e3180465940","doi":"https://doi.org/10.1097/ppo.0b013e3180465940","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ppo.0b013e3180465940","pdf_url":null,"source":{"id":"https://openalex.org/S4210176243","display_name":"The Cancer Journal","issn_l":"1528-9117","issn":["1528-9117","1540-336X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Cancer Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112194742","display_name":"Mari Nakabayashi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mari Nakabayashi","raw_affiliation_strings":["Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002491634","display_name":"Jonathan P. Ling","orcid":"https://orcid.org/0000-0003-1927-9729","observed_orcids":["https://orcid.org/0000-0003-1927-9729"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jonathan Ling","raw_affiliation_strings":["Lank Center for Genitourinary Oncology, Department of Medical Oncology, and \u2020Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lank Center for Genitourinary Oncology, Department of Medical Oncology, and \u2020Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066816851","display_name":"Wanling Xie","orcid":"https://orcid.org/0000-0001-5995-8000","observed_orcids":["https://orcid.org/0000-0001-5995-8000"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wanling Xie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017334876","display_name":"Meredith M. Regan","orcid":"https://orcid.org/0000-0002-2428-6109","observed_orcids":["https://orcid.org/0000-0002-2428-6109"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meredith M. Regan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5078027978","display_name":"William K. Oh","orcid":"https://orcid.org/0000-0001-5113-8147","observed_orcids":["https://orcid.org/0000-0001-5113-8147"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"William K. Oh","raw_affiliation_strings":["Lank Center for Genitourinary Oncology, Department of Medical Oncology, and \u2020Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lank Center for Genitourinary Oncology, Department of Medical Oncology, and \u2020Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5002491634","https://openalex.org/A5078027978","https://openalex.org/A5112194742"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"],"apc_list":null,"apc_paid":null,"fwci":2.5933,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.89573602,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"13","issue":"2","first_page":"125","last_page":"129"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vinorelbine","display_name":"vinorelbine","score":0.9290000200271606},{"id":"https://openalex.org/keywords/estramustine","display_name":"estramustine","score":1.0},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/second-line-chemotherapy","display_name":"second-line chemotherapy","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.9049999713897705},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.8939999938011169},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9909999966621399},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.699999988079071},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.9100000262260437}],"concepts":[{"id":"https://openalex.org/C2780350996","wikidata":"https://www.wikidata.org/wiki/Q420532","display_name":"Vinorelbine","level":4,"score":0.9150468707084656},{"id":"https://openalex.org/C2780201970","wikidata":"https://www.wikidata.org/wiki/Q412939","display_name":"Estramustine","level":5,"score":0.9068331718444824},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.7028235197067261},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6864430904388428},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6264127492904663},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5855076313018799},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.5694432854652405},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46278008818626404},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4124957323074341},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40077319741249084},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.39226067066192627},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.366835355758667},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35924166440963745},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10350829362869263},{"id":"https://openalex.org/C2994223898","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate disease","level":4,"score":0.06897452473640442},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.04628729820251465},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077235","descriptor_name":"Vinorelbine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004961","descriptor_name":"Estramustine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008942","descriptor_name":"Mitoxantrone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014747","descriptor_name":"Vinblastine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014747","descriptor_name":"Vinblastine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017430","descriptor_name":"Prostate-Specific Antigen","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/ppo.0b013e3180465940","doi":"https://doi.org/10.1097/ppo.0b013e3180465940","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ppo.0b013e3180465940","pdf_url":null,"source":{"id":"https://openalex.org/S4210176243","display_name":"The Cancer Journal","issn_l":"1528-9117","issn":["1528-9117","1540-336X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Cancer Journal","raw_type":"journal-article"},{"id":"pmid:17476141","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17476141","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer journal (Sudbury, Mass.)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1868905893","https://openalex.org/W1971541628","https://openalex.org/W1971579914","https://openalex.org/W2044408398","https://openalex.org/W2051436873","https://openalex.org/W2060598630","https://openalex.org/W2080439368","https://openalex.org/W2082238401","https://openalex.org/W2110110495","https://openalex.org/W2120292596","https://openalex.org/W2155679349","https://openalex.org/W2157549109","https://openalex.org/W2411858122","https://openalex.org/W2415683488","https://openalex.org/W2885204309"],"related_works":["https://openalex.org/W2044408398","https://openalex.org/W2157549109","https://openalex.org/W2334757552","https://openalex.org/W2153997857","https://openalex.org/W1868905893","https://openalex.org/W2261499473","https://openalex.org/W4234222353","https://openalex.org/W2060598630","https://openalex.org/W2112766786","https://openalex.org/W4251622075"],"abstract_inverted_index":{"BACKGROUND:":[0],"Vinorelbine":[1],"(VRL)":[2],"in":[3,10,32,42,59,131,136,143,150,177,194],"combination":[4,202],"with":[5,39,46,51,74,101,145,196,200],"estramustine":[6,148,206],"has":[7],"known":[8,23],"efficacy":[9,26],"the":[11,25,201],"initial":[12],"chemotherapeutic":[13],"management":[14],"of":[15,27,110,168,179,203],"hormone-refractory":[16],"prostate":[17],"cancer":[18],"(HRPC).":[19],"However,":[20],"little":[21],"is":[22],"about":[24],"VRL":[28,47,75,85,102,146,154,169,186,204,214],"as":[29,48],"second-line":[30,49,184],"chemotherapy":[31,50],"HRPC.":[33,197],"METHODS:":[34],"We":[35],"retrospectively":[36],"identified":[37],"patients":[38,71,81,88,94,144,151,195],"HRPC":[40],"treated":[41,73,100,199],"a":[43,183,208],"single":[44],"institution":[45],"or":[52,173],"without":[53],"estramustine.":[54,92],"Patient":[55],"baseline":[56],"characteristics,":[57],"declines":[58,106],"prostate-specific":[60,104],"antigen,":[61],"performance":[62],"status,":[63],"toxicities,":[64],"and":[65,78,86,133,147,190,205],"survival":[66,120,139,210],"were":[67,72],"assessed.":[68],"RESULTS:":[69],"Thirty-nine":[70],"between":[76],"1999":[77],"2005.":[79],"Twenty-one":[80],"(54%)":[82],"received":[83,153],"single-agent":[84],"18":[87],"(46%)":[89],"had":[90],"concomitant":[91],"Seven":[93],"(17.9%,":[95],"95%":[96],"confidence":[97],"interval":[98],"7.5%-33.6%)":[99],"experienced":[103,207],"antigen":[105],">or=50%.":[107],"Median":[108,118,138],"duration":[109],"therapy":[111],"was":[112,121,128,140,170,191],"1.4":[113],"months":[114,123,135,157],"(range":[115,124],"0.2-14.0":[116],"months).":[117],"overall":[119],"6.9":[122],"1.4-29.9":[125],"months);":[126],"it":[127],"16.1":[129],"month":[130],"responders":[132],"5.5":[134],"nonresponders.":[137],"significantly":[141],"longer":[142,209],"than":[149,211],"who":[152],"alone":[155],"(8.5":[156],"versus":[158],"4.1":[159],"months,":[160],"P=0.05).":[161],"The":[162],"most":[163],"common":[164],"reversible":[165],"adverse":[166],"effect":[167],"grade":[171],"1":[172],"2":[174],"fatigue":[175],"observed":[176],"36%":[178],"patients.":[180],"CONCLUSIONS:":[181],"As":[182],"chemotherapy,":[185],"demonstrated":[187],"moderate":[188],"activity":[189],"well":[192],"tolerated":[193],"Patients":[198],"those":[212],"receiving":[213],"alone.":[215]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}